Ceptaris Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ceptaris Therapeutics, Inc.
Vanderbilt launches new biotech with Deerfield aimed at reworking the drug development paradigm, while also expanding its cancer research work with BI. Grunenthal partners with Katholieke Universiteit Leuven to investigate ion channel modulation approaches in pain.
A review of biopharma startup dealmaking and financing activity from January through March 2017, based on data from Strategic Transactions, showed a 19% decline in startup financing compared with the fourth quarter of 2016, but big pharmas provided capital in the form of alliance fees.
Jeffrey Patrick joins Ohio State's effort to develop cancer drugs from internal research, bringing a biopharma viewpoint to optimizing such programs before the deal-making effort starts. Plus, the EMA sets a framework for academic interaction, and more tech transfer news.
The social media site, now in its second decade, has over 350,000 users who report on more than 2,500 diseases. It has begun partnering with biopharma companies eager to engage with members and mine patient-reported data on diseases and outcomes.
- Other Names / Subsidiaries
- Yaupon Therapeutics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.